A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)
| Excerpt | Reference |
|---|
| "Fibrositis (fibromyalgia) is best treated by attaining patient acceptance of and compliance with a comprehensive treatment program." | ( Gatter, RA, 1986) |
| "Primary fibromyalgia is a common but often unrecognized rheumatic condition." | ( Calabro, JJ; Masi, AT; Shah, IK; Yunus, M, 1982) |
| "Fibromyalgia is rarely included in the differential diagnosis of dyspnea, and timely diagnosis and treatment may be delayed." | ( Albert, RK; Kreck, T; Weiss, DJ, 1998) |
| "Fibromyalgia is a common rheumatologic disorder that is often difficult to treat effectively." | ( Gums, JG; Schmidt, SO; Smith, JD; Terpening, CM, 2001) |
| "Fibromyalgia is a chronic condition that is diagnosed primarily by the presence of generalized pain along with tenderness on palpation of certain body regions." | ( Cohen, HM; Freedenfeld, RN; Fuchs, PN; Jewell, C; Kiser, RS, 2001) |
| "Fibromyalgia is a form of non-articular rheumatism characterised by long term (>3 months) and widespread musculoskeletal aching, stiffness and pressure hyperalgesia at characteristic soft tissue sites, called soft tissue tender points." | ( Maes, M; van West, D, 2001) |
| "Fibromyalgia is a syndrome characterized by chronic musculoskeletal pain and fatigue without biological detectable disturbances." | ( Goichot, B; Grunenberger, F; Perrin, AE; Schlienger, JL, 2001) |
| "Fibromyalgia is a stress-related disorder characterized by chronic pain, memory impairment, and neuroendocrine aberrations." | ( Ho, I; Hoover, K; Lynch, G; McGuffin, S; Salmon, P; Sephton, SE; Studts, JL; Weissbecker, I, 2003) |
| "Fibromyalgia is a common and disabling chronic pain syndrome." | ( Calandre, EP; Dominguez, I; García-Leiva, JM; Hidalgo, J; Rico-Villademoros, F, 2005) |
| "Fibromyalgia is a common disorder characterized by chronic widespread pain that affects an estimated 2% of the general population." | ( Wood, PB, 2006) |
| "Fibromyalgia is a prevalent syndrome characterized by chronic pain, fatigue, and insomnia." | ( Alonso, C; Coe, CL; Loevinger, BL; Muller, D, 2007) |
| "Fibromyalgia is a significant clinical problem associated with generalized pain and significant interference with daily activities." | ( Freedenfeld, RN; Fuchs, PN; Kiser, RS; Murray, M, 2006) |
| "The pain of fibromyalgia is described in terms suggestive of the pain in muscles following extreme exertion and anaerobic metabolism." | ( Ali, A; Faridi, Z; Greene, L; Katz, DL, 2007) |
| "Fibromyalgia is a common disorder that is characterized by chronic widespread pain, tenderness to light palpation, fatigue and sleep disturbances." | ( Holman, AJ; Jones, KD; Wood, PB, 2007) |
| "Fibromyalgia is characterized by chronic widespread pain and bodily tenderness and is often accompanied by affective disturbances." | ( Bushnell, MC; Chizh, BA; Dagher, A; Hakyemez, H; Jaeger, E; Rabiner, EA; Schweinhardt, P; Wood, PB, 2007) |
| "Fibromyalgia is a chronic pain syndrome, common in primary care." | ( Allaz, AF; Cedraschi, C; Girard, E; Luthy, C; Rentsch, D, 2007) |
| "Fibromyalgia is a common and disabling syndrome." | ( Clauw, DJ, 2008) |
| "Fibromyalgia is a disorder characterized by chronic widespread pain." | ( Harth, F; Kaiber, F; Machado, F; Malucelli, T; Schafranski, MD; Schmidt, C; Takeshi, H, 2009) |
| "The etiology of fibromyalgia is not clearly understood." | ( Akkuş, S; Eriş, S; Naziroğlu, M; Yalman, K; Yener, M; Yilmaz, N, 2009) |
| "Fibromyalgia is a prevalent and disabling disorder characterized by widespread pain and other symptoms such as insomnia, fatigue or depression." | ( Alda, M; Andrés, E; del Hoyo, YL; García-Campayo, J; Luciano, JV; Magallón, R; Rodero, B; Serrano-Blanco, A, 2009) |
| "Fibromyalgia is a prevalent and disabling disorder characterized by widespread pain and other symptoms such as insomnia, fatigue or depression." | ( Alda, M; Andrés, E; del Hoyo, YL; García-Campayo, J; Luciano, JV; Magallón, R; Rodero, B; Serrano-Blanco, A, 2009) |
| "Fibromyalgia is associated with reductions in gray matter density within brain regions ostensibly involved in phenomena related to the disorder, including enhanced pain perception, cognitive dysfunction, and abnormal stress reactivity." | ( Glabus, MF; Patterson, JC; Simpson, R; Wood, PB, 2009) |
| "Patients with fibromyalgia are at increased risk to experience increased and prolonged postoperative pain." | ( Englbrecht, JS; Pogatzki-Zahn, EM; Schug, SA, 2009) |
| "Fibromyalgia is a prevalent and burdensome disorder characterized by chronic widespread pain and complex comorbid symptoms." | ( Aoki, T; Matsuoka, N; Nagakura, Y; Oe, T, 2009) |
| "(1) Fibromyalgia is characterised by a range of symptoms that include muscle pain, fatigue and sleep disorders." | ( , 2009) |
| "Fibromyalgia is an ill-defined condition that causes pain and disability but still lacks effective treatment." | ( Amital, D; Amital, H; Leader, A; Rubinow, A, 2009) |
| "Fibromyalgia is a significant health problem for women of working age." | ( Kukkurainen, ML; Mikkelsson, M; Peltokallio, L; Sallinen, M, 2010) |
| "Fibromyalgia is a chronic pain disorder characterized by widespread pain, stiffness, insomnia, fatigue and distress." | ( Staud, R, 2010) |
| "Fibromyalgia is a disorder characterized by chronic widespread musculoskeletal pain and stiffness." | ( Briley, M, 2010) |
| "Fibromyalgia is a chronic pain syndrome with unknown etiology." | ( Bonal, P; Bullon, P; Campa, F; Carmona López, IM; Cordero, MD; Cotán, D; De Miguel, M; Garrido Maraver, J; Gómez Izquierdo, L; Moreno Fernández, AM; Navas, P; Sánchez Alcázar, JA, 2010) |
| "Fibromyalgia is a chronic condition associated with widespread pain, sleep disturbance and disability." | ( Bowrin, K; Choy, E; Lloyd, A; Richards, S; Sadosky, A; Watson, P; Zlateva, G, 2010) |
| "Fibromyalgia is a condition characterized by long term body-wide pain and tender points in joints, muscles and soft tissues." | ( Ramachandran, VS; Seckel, EL, 2010) |
| "Fibromyalgia is a chronic disorder of uncertain aetiology, more common in women than in man, characterized by widespread pain, muscle tenderness and decreased pain threshold to pressure and other stimuli." | ( Grembiale, RD; Pipicelli, G; Ursini, F, 2010) |
| "Fibromyalgia is a difficult-to-treat chronic pain syndrome that affects 2% of the US population." | ( Cushman, T; Gardner, H; McDonagh, M; Siler, AC; Yanit, K, 2011) |
| "Fibromyalgia is a debilitating, chronic pain disorder typically present with allodynia and hyperalgesia." | ( Arora, V; Chopra, K; Kuhad, A, 2011) |
| "Fibromyalgia is characterised by chronic musculoskeletal pain and multiple symptoms including fatigue, multidimensional function impairment, sleep disturbance and tenderness." | ( Bennett, RM; Benson, BA; Choy, EH; Lai, C; Spaeth, M; Wang, YG, 2012) |
| "Fibromyalgia is a chronic widespread pain disorder commonly associated with comorbid symptoms, including fatigue and nonrestorative sleep." | ( Arnold, LM; Clauw, DJ; Dunegan, LJ; Turk, DC, 2012) |
| "Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness." | ( Nishioka, K; Ohkura, M; Ohta, H; Oka, H; Suzuki, M; Usui, C, 2012) |
| "Fibromyalgia is a prevalent chronic rheumatic disease of great clinical importance." | ( Andrés, E; Arcega, R; Garcia-Campayo, J; López-del-Hoyo, Y; Magallon, R; Masluk, B; Olivan-Blázquez, B; Pérez-Yus, MC; Puebla, M; Roca, M, 2013) |
| "Fibromyalgia is characterized by chronic widespread pain and sleep disturbances." | ( de Oliveira, AR; Góes, SM; Homann, D; Leite, N; Lopes, AL; Louzada, FM; Roizenblatt, S, 2013) |
| "Fibromyalgia is a syndrome characterized by the presence of chronic widespread pain, representing sensitization of the central nervous system." | ( Ablin, JN; Buskila, D, 2013) |
| "Fibromyalgia is a common chronic pain disorder with unclear etiology." | ( Kim, SC; Landon, JE; Solomon, DH, 2013) |
| "Fibromyalgia is a pain disorder associated with frequent comorbid mood, anxiety, and sleep disorders." | ( Agabio, R; Carboni, M; Carta, MG; Mameli, S; Marchi, A; Melis, MR; Minerba, L; Pili, A; Pisanu, GM; Sardo, S; Trincas, G, 2014) |
| "Fibromyalgia is a painful disease affecting 1-2% of the United States population." | ( Smith, SM; Trinkley, KE; VanderWeide, LA, 2015) |
| "Fibromyalgia is a chronic pain syndrome characterized by widespread pain, fatigue, and memory and mood disturbances." | ( Clauw, DJ; Hampson, JP; Harris, RE; Harte, S; Ichesco, E; Kairys, A; Peltier, S; Schmidt-Wilcke, T, 2014) |
| "Treatment of fibromyalgia is an unmet medical need." | ( Mukae, T; Uchida, H; Ueda, H, 2015) |
| "Fibromyalgia is diagnosed using an updated set of clinical criteria that no longer depend on tender point examination; laboratory testing may rule out other disorders that commonly present with fatigue, such as anemia and thyroid disease." | ( Kodner, C, 2015) |
| "Fibromyalgia is a diffuse chronic pain condition that occurs predominantly in women and may be under-reported in men." | ( Robinson, TD; White, HD, 2015) |
| "Fibromyalgia is a clinically well-defined chronic condition with a biopsychosocial aetiology." | ( Cantrell, SE; Häuser, W; Nishishinya, MB; Urrútia, G; Walitt, B, 2015) |
| "Fibromyalgia is characterized by widespread pain and is often accompanied by accessory symptoms." | ( Alev, L; Mizuno, H; Murakami, M; Nishioka, K; Ochiai, T; Osada, K, 2015) |
| "Fibromyalgia is characterized by chronic generalized pain accompanied by a wide range of clinical manifestations." | ( Calandre, EP; Rico-Villademoros, F; Slim, M, 2015) |
| "Fibromyalgia is a disorder that is part of a spectrum of syndromes that lack precise classification." | ( Borchers, AT; Gershwin, ME, 2015) |
| "Fibromyalgia is a syndrome of chronic widespread pain typically accompanied by fatigue, nonrestorative sleep, cognitive dysfunction, and mood disorders." | ( McCarthy, J, 2016) |
| "Fibromyalgia is a syndrome characterized by chronic widespread pain and associated with sleep disturbance, depression, fatigue, and cognitive dysfunction." | ( Chaparro, LE; DuMerton-Shore, D; Gilron, I; Holden, RR; Milev, R; Towheed, T; Tu, D; Walker, S, 2016) |
| "Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue." | ( Häuser, W; Klose, P; Phillips, T; Üçeyler, N; Walitt, B, 2016) |
| "Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue affecting approximately 2% of the general population." | ( Fitzcharles, MA; Häuser, W; Klose, P; Phillips, T; Walitt, B, 2016) |
| "Fibromyalgia is more common in women." | ( Cooper, TE; Derry, S; Moore, RA; Wiffen, PJ, 2017) |
| "Fibromyalgia is a prevalent disorder characterized by chronic widespread pain and complex symptoms." | ( Abd El Fattah, MA; Kenawy, SA; Radwan, RR; Shabaan, EA; Shibrya, EE, 2017) |
| "ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment." | ( Arkfeld, DG; Chen, CL; Metyas, S; Solyman, J; Yeter, K, 2018) |
| "Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain and an extensive array of other symptoms including disordered sleep, fatigue, depression and anxiety." | ( Bonomini, F; Favero, G; Lavazza, A; Rezzani, R; Rodella, LF; Stacchiotti, A; Trapletti, V, 2017) |
| "Fibromyalgia is a refractory disease characterized by chronic intractable pain and psychological suffering, the cause of which has not yet been elucidated due to its complex pathology." | ( Hashimoto, R; Hayakawa, K; Hayaki, C; Hosoi, M; Inoue, K; Iwaki, R; Kanba, S; Kato, TA; Ohgidani, M; Sagata, N; Sudo, N; Tsuda, M, 2017) |
| "Fibromyalgia is a chronic widespread pain condition affecting millions of people worldwide." | ( Gilron, I; Moore, RA; Shum, B; Thorpe, J; Wiffen, PJ, 2018) |
| "Fibromyalgia is a clinically defined chronic condition of unknown etiology characterized by chronic widespread pain that often co-exists with sleep disturbances, cognitive dysfunction and fatigue." | ( Häuser, W; Klose, P; Üçeyler, N; Walitt, B; Welsch, P, 2018) |
| "Fibromyalgia is a poorly understood, chronically disabling pain syndrome." | ( Arout, CA; Bastian, LA; Rosenheck, RA; Sofuoglu, M, 2018) |
| "Fibromyalgia is a clinically defined chronic condition of unknown etiology characterised by chronic widespread pain, sleep disturbance, cognitive dysfunction, and fatigue." | ( Bernardy, K; Derry, S; Häuser, W; Moore, RA; Welsch, P, 2018) |
| "Fibromyalgia is characterized by widespread and chronic pain, and its prevalence is increasing worldwide." | ( Cardot, JM; Delage, N; Dualé, C; Giron, F; Macian, N; Marcaillou, F; Pereira, B; Picard, P; Pickering, G; Sickout-Arondo, S, 2018) |
| "Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective." | ( Costa, J; Ferreira-Dos-Santos, G; Sousa, DC; Vaz-Carneiro, A, 2018) |
| "Fibromyalgia is a multifaceted chronic pain condition of unknown etiology." | ( Jarrahi, B; Mackey, S; Martucci, KT; Nilakantan, AS, 2018) |
| "Fibromyalgia is a chronic disorder with a very complex symptomatology." | ( Cirrito, C; Lleshi, A; Pavanello, M; Piasentin, C; Taibi, R; Tirelli, U, 2019) |
| "Fibromyalgia is characterized by myalgia and a combination of different symptoms including pain, fatigue, insomnia, morning rigidity, depression and a reduction in every-day functioning." | ( Ferreira, I; Moore, P; Ortigoza, Á, 2019) |
| "Fibromyalgia is a disease characterised as generalised chronic primary pain that causes functional disability and a reduction in patients' quality of life, without specific pathophysiology or appropriate treatment." | ( Brusco, I; Cunha, TM; Ferreira, J; Fischer, S; Justino, AB; Machado-de-Ávila, RA; Oliveira, SM; Scussel, R; Silva, CR, 2019) |
| "The pathogenesis of fibromyalgia is still unknown." | ( Alfosea-Cuadrado, G; Blasco-Serra, A; Cervera-Ferri, A; González-Soler, EM; Lloret, A; Martínez-Ricós, J; Teruel-Martí, V; Valverde-Navarro, AA, 2020) |
| "Fibromyalgia is a heterogeneous condition that appears to be associated with physiological and biochemical disturbances of pain modulation, and that consequently affects numerous other facets of life." | ( Civile, V; da Rocha, AP; da Silva Vieira, AG; Mizzaci, CC; Nunes Pinto, ACP; Trevisani, VFM, 2020) |
| "Fibromyalgia is a refractory syndrome characterized by chronic wayward pain and complex co-morbid psychological trepidation." | ( Bhatti, R; Garg, S; Kaur, A; Singh, AP; Singh, L, 2020) |
| "Fibromyalgia is a common and challenging chronic pain disorder with few, if any, highly effective and well-tolerated treatments." | ( Gilron, I; Gray, C; Holden, R; Milev, R; Robb, S; Towheed, T; Tu, D; Wang, L; Ziegler, D, 2021) |
| "Fibromyalgia is commonly considered a stress-related chronic pain disorder, and daily stressors are known triggers." | ( Chen, CC; Chen, CH; Hsu, CY; Hung, CH; Lai, CL; Lee, CH; Lin, HF; Tsai, MH, 2020) |
| "Fibromyalgia is a complex disease process that is as prevalent as it is poorly understood." | ( Berger, AA; Eskander, JP; Gilbert, E; Kaye, AD; Keefe, J; Urits, I; Viswanath, O; Winnick, A; Yazdi, C, 2020) |
| "Fibromyalgia is characterized by the amplification of central nervous system pain with concomitant fatigue, sleep, mood disorders, depression, and anxiety." | ( Antunes, FTT; Campos, MM; Correa, ÁP; de Oliveira, IB; de Souza, AH; do Nascimento Cordeiro, M; Gomez, MV; Klein, CP; Pedron, C; Rebelo, IN, 2021) |
| "Fibromyalgia is a potentially disabling chronic disease, characterized by widespread pain and a range of comorbidities such as hypertension." | ( Brusco, I; Justino, AB; Machado-de-Ávila, RA; Oliveira, SM; Scussel, R; Silva, CR, 2021) |
| "Fibromyalgia is a common, chronic, and generalized pain syndrome that is often associated with comorbid depression." | ( Bhatti, R; Kaur, A; Singh, AP; Singh, L, 2021) |
| "Fibromyalgia is a common chronic pain condition of unknown aetiology, although mitochondrial dysfunction, oxidative stress, and inflammation have been implicated in the pathophysiology of this disorder." | ( Hargreaves, IP; Mantle, D, 2021) |
| "Fibromyalgia is a disorder of pain processing with characteristic symptoms." | ( Bendinger, T; Perfitt, JS, 2021) |
| "Fibromyalgia is a centralized multidimensional chronic pain syndrome, but its pathophysiology is not fully understood." | ( Andronesi, OC; Berry, MP; Edwards, RR; Ellingsen, DM; Grahl, A; Isaro, L; Lazaridou, A; Lee, J; Loggia, ML; Napadow, V; Paschali, M; Ratai, EM; Torrado-Carvajal, A; Wasan, AD; Weerasekera, A, 2021) |
| "Fibromyalgia is a chronic multidimensional pain disease with no curative treatment currently available." | ( Dangoisse, M; Fils, JF; Gillain, A; Javorcikova, Z; Lechat, JP; Nikis, S; Van der Linden, P, 2021) |
| "Fibromyalgia is a chronic syndrome characterized by widespread muscular pain and tenderness with no evidence of soft tissue inflammation." | ( Bou Khalil, R; Zarzour, M, 2022) |
| "Fibromyalgia is characterized by diffuse musculoskeletal pain and fatigue." | ( Dirawi, N; Habib, G, 2022) |
| "Fibromyalgia is a clinical condition that affects 1% to 5% of the population." | ( Cordaro, M; Cuzzocrea, S; D'Amico, R; Di Paola, D; Di Paola, R; Franco, G; Fusco, R; Genovese, T; Impellizzeri, D; Marino, Y; Siracusa, R, 2022) |
| "Fibromyalgia is a prevalent disorder manifesting with widespread musculoskeletal pain and central sensitization, as well as fatigue, sleep issues, psychologic distress, and poor quality of life." | ( Barman, RA; D'Souza, RS; Hagedorn, JM; Schappell, JB, 2023) |
| "Fibromyalgia is a complex pain-focused syndrome." | ( Hayun, Y; Hershkovich, O; Lotan, R; Oscar, N; Shtein, A, 2023) |
| "Fibromyalgia is a heterogenous primary pain syndrome whose severity has been associated with descending pain modulatory system (DPMS) function and functional connectivity (FC) between pain processing areas." | ( Alves, RL; Bruck, SM; Caumo, W; da Silveira Alves, CF; de Oliveira Franco, Á; de Oliveira Venturini, G; Fregni, F; Ramalho, L; Tomedi, R; Torres, ILS; Vicuña, P, 2022) |
| "Fibromyalgia is a chronic, centralized pain syndrome characterized by disordered processing of painful stimuli." | ( Dang, L; Vandal, C; Winslow, BT, 2023) |
| "Drug therapy for fibromyalgia is limited by incomplete efficacy and dose-limiting adverse effects (AEs)." | ( Gilron, I; Holden, RR; Milev, R; Robb, S; Towheed, T; Tu, D, 2023) |
| "Fibromyalgia is a chronic pain syndrome with unsatisfactory response to current treatments." | ( Ablin, JN; Aloush, V; Catalogna, M; Doenyas-Barak, K; Efrati, S; Finci, S; Fishlev, G; Hadanny, A; Korin, C; Lang, E; Meir Genuth, O; Polak, N; Tzidky, RY, 2023) |
| "Fibromyalgia is a widespread chronic pain syndrome associated with several comorbid conditions that affect the quality of patients' life." | ( Abd Elmaaboud, MA; Awad, MM; El-Shaer, RAA; Kabel, AM, 2023) |
| "Fibromyalgia is not generally recognized as a modifiable risk factor prior to THA." | ( Kagan, R; Mildren, ME; Morrell, AT; Smith, S; Yoo, J, 2023) |
| "Fibromyalgia is a chronic pain syndrome with a multifactorial pathophysiology affecting 2-8 % of the population." | ( Abdelghany, AK; Desouky, MK; Ibrahim, MFG; Mokhemer, SA, 2023) |
| "Fibromyalgia is a prototypical central pain disorder, which is often used as a model to study chronic pain disorders." | ( Gulur, P; Nelli, A; Wright, MC, 2023) |
| "Fibromyalgia is a chronic pain syndrome that is considered a pain processing disorder; its pathophysiology is not completely understood." | ( Flynn, D, 2023) |
| Excerpt | Reference |
|---|
| "Fibromyalgia Impact Questionnaire outcomes were used for the individuals' treatment and combined across patients for sample-based analyses." | ( Feuer, JM; Fischer, PA; Goldenberg, DL; Kieval, RI; Mogavero, N; Rapoport, RJ; Ruthazer, R; Schmid, CH; Selker, HP; Stotsky, SA; Winston, E; Zucker, DR, 2006) |
| "Fibromyalgia Impact Questionnaire (FIQ), Pittsburgh Sleep Quality Index (PSQI), a Clinical Global Impression improvement scale (CGIi), and a scale evaluating the severity of fibromyalgia symptoms were administered at 4 week intervals for 12 weeks." | ( Calandre, EP; Hidalgo, J; Rico-Villademoros, F, 2007) |
| "Fibromyalgia impact questionnaire was used for functional assessment." | ( Sendur, OF; Tastaban, E; Turan, Y; Ulman, C, 2008) |
| "Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire, and a visual analog scale (VAS) for pain were applied before the first lidocaine infusion, immediately after the fifth infusion and 30 days after the fifth infusion." | ( Harth, F; Kaiber, F; Machado, F; Malucelli, T; Schafranski, MD; Schmidt, C; Takeshi, H, 2009) |
| "The Fibromyalgia Impact Questionnaire (FIQ) is a disease-specific composite instrument that measures the effect of problems experienced by patients with fibromyalgia (FM)." | ( Bennett, RM; Bushmakin, AG; Cappelleri, JC; Sadosky, AB; Zlateva, G, 2009) |
| "The fibromyalgia impact questionnaire (FIQ) and clinical examination were done before tegaserod treatment and 1 month after." | ( Kalichman, L; Malnick, S; Novochatko, G; Polishchuck, I; Reitblat, T; Zamir, D, 2009) |
| "The fibromyalgia impact questionnaire (FIQ) tiredness item score (0 to 10 scale) was used to define tiredness subgroups." | ( Bennett, R; Bradley, LA; Chappell, AS; D'Souza, DN; Moldofsky, H; Russell, IJ; Wang, F; Wohlreich, MM, 2010) |
| "Fibromyalgia affects an estimated 2% of the general U." | ( Thiessen, CN; Traynor, AP; Traynor, LM, 2011) |
| "Pain intensity, fibromyalgia impact on quality of life, physical activity level and fall prevalence were assessed." | ( Góes, SM; Homann, D; Leite, N; Rodacki, AL; Shay, BL; Stefanello, JM, 2012) |
| "Fibromyalgia Impact Questionnaire (FIQ) was the main outcome measure, and was administered at baseline and at weeks 4, 8, and 12." | ( Calandre, EP; Hidalgo-Tallón, J; Menéndez-Cepero, S; Rodríguez-López, CM; Vilchez, JS, 2013) |
| "The Fibromyalgia Impact Questionnaire (FIQ) is a patient-reported outcome that evaluates the impact of fibromyalgia (FM) on daily life." | ( Bushmakin, AG; Cappelleri, JC; Chandran, AB; Zlateva, G, 2013) |
| "Fibromyalgia Impact Questionnaire-Revised, Quality of Life Scale, Arthritis Self-efficacy Scale, and COPE Scales for CSs were administered to both the groups." | ( Agarwal, GG; Alok, R; Das, SK; Salwahan, L; Srivastava, R; Tiwari, SC, 2014) |
| "Components of Fibromyalgia Impact Questionnaire-Revised, namely, pain, function, and symptoms, were found to be significantly and negatively associated with problem-focused coping (P < 0." | ( Agarwal, GG; Alok, R; Das, SK; Salwahan, L; Srivastava, R; Tiwari, SC, 2014) |
| "Fibromyalgia impact and pain were analyzed by Fibromyalgia Impact Questionnaire (FIQ), tender points (TPs), visual analog scale (VAS)." | ( García-Pinillos, F; Latorre Román, PÁ; Santos E Campos, MA, 2015) |
| "Fibromyalgia Impact Questionnaire scores were 42." | ( Chaparro, LE; DuMerton-Shore, D; Gilron, I; Holden, RR; Milev, R; Towheed, T; Tu, D; Walker, S, 2016) |
| "They answered the Fibromyalgia Impact Questionnaire (FIQ), Perceived Stress Questionnaire (PSQ) and McGill Pain Questionnaire (MPQ-Br), and collected saliva to evaluate CC before and after the end of each month." | ( Borghi, F; da Silva, LGRV; de Oliveira Crege, DRX; de Oliveira, FR; Gomes, AE; Grassi-Kassisse, DM; Luiz de Souza, A; Trevisan, G; Visnardi Gonçalves, LC, 2018) |
| "They filled out the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form-36 Health Status Questionnaire (SF-36) at baseline and 6 to 12 months after the FTP." | ( Hwang, JM; Kim, CH; Lee, BJ; Oh, TH; Park, D, 2019) |
| "The Fibromyalgia Impact Questionnaire (FIQ) was used for the assessment of FM severity." | ( Genç, H; Mansız Kaplan, B; Mülkoğlu, C; Selvi, AB; Taşkın, S; Vural, S, 2020) |
| "The Fibromyalgia Impact Questionnaire (FIQ) was applied at pre- and postintervention moments and in five visits over eight weeks." | ( Bittencourt, PCT; Chaves, C; Pelegrini, A, 2020) |
| "The data from the fibromyalgia impact questionnaire (FIQ) and the physical and mental subscales short form 36 (SF36) were extracted at last follow-up." | ( Colarossi, G; Eschweiler, J; Knobe, M; Maffulli, N; Migliorini, F; Tingart, M, 2022) |
| "The Revised Fibromyalgia Impact Questionnaire (FIQR), Short-Form Health Survey (SF-12), pain visualized analog scale (pain VAS), Beck Depression Inventory-II (BDI-II), polysymptomatic distress scale (PSD) and serum BDNF were measured and compared at baseline and 4 weeks after treatment in FM group." | ( Bidari, A; Gharibpoor, F; Ghavidel-Parsa, B, 2022) |
| "The fibromyalgia impact questionnaire (FIQ), Pittsburgh sleep quality index (PSQI), and 12-item short-form health survey (SF-12) were used for evaluation pre- and post-intervention." | ( Soydaş, N; Sucuoğlu, H, 2023) |
| "The Fibromyalgia Impact Questionnaire (FIQ1, FIQ2) was applied and compared before and after IV iron treatment." | ( Aydemir, AE; Gürcü, S; Hamarat, H; Kıvanç, BK, 2023) |
| Excerpt | Reference |
|---|
| "In conclusion, 28 days treatment of fibromyalgia patients with 5 mg tropisetron resulted in significant pain reduction, which was most pronounced after 10 days with a further reduction up to day 28." | ( Haus, U; Müller, W; Späth, M; Stratz, T; Varga, B, 2000) |
| "Unfortunately, the pharmacological treatment of fibromyalgia remains problematic." | ( Cohen, HM; Freedenfeld, RN; Fuchs, PN; Jewell, C; Kiser, RS, 2001) |
| "Short-term treatment of fibromyalgia patients with 5 mg tropisetron for 10 days proved to be efficacious and well tolerated." | ( Brückle, W; Färber, L; Kötter, I; Lautenschläger, J; Müller, W; Neeck, G; Peter, HH; Pongratz, D; Späth, M; Stratz, TH; Welzel, D; Zöller, B, 2001) |
| "Individuals who were seeking treatment for fibromyalgia had a higher production rate of responses indicating fear and phobic concerns (FEAR) than individuals in the other 2 groups." | ( Panek, PE; Skowronski, JJ; Wagner, EE, 2002) |
| "Duloxetine treatment improved fibromyalgia symptoms and pain severity regardless of baseline status of major depressive disorder." | ( Arnold, LM; Crofford, LJ; Detke, MJ; Goldstein, DJ; Iyengar, S; Lu, Y; Wohlreich, M, 2004) |
| "An interdisciplinary guideline for the treatment of fibromyalgia syndrome (FMS) and chronic widespread pain (CWP) was developed in cooperation with ten German medical and psychological associations and two patients' self-help organizations." | ( Berliner, M; Brückle, W; Ehlers, S; Häuser, W; Mönkemöller, K; Moradi, B; Nutzinger, DO; Petzke, F; Sommer, C; Uçeyler, N; Winter, E; Wörz, R, 2008) |
| "Increasing use of these agents to treat fibromyalgia (FM) raises concern for this unexpected toxicity in a new group of patients." | ( Holman, AJ, 2009) |
| "However response to treatment of fibromyalgia symptoms with paroxetine CR was not associated with a history of depressive and/or anxiety disorders." | ( Krulewicz, S; Mannelli, P; Marks, DM; Masand, PS; Pae, CU; Patkar, AA; Peindl, K, 2009) |
| "Composite responder rates for the treatment of fibromyalgia and fibromyalgia pain (co-primary efficacy variables) were generally higher with milnacipran 100 or 200 mg/day (in two divided doses) than with placebo after 12 weeks of fixed-dose treatment." | ( Chwieduk, CM; McCormack, PL, 2010) |
| "A broad range of drugs has been used to treat fibromyalgia." | ( Thiessen, CN; Traynor, AP; Traynor, LM, 2011) |
| "There is a changing pattern of drug treatment in fibromyalgia, consisting mostly of decreased NSAID and amitriptyline use and an increase in NCAD." | ( Häuser, W; Katz, RS; Lee, YC; Michaud, KD; Walitt, BT; Wolfe, F, 2013) |
| "Canabinoid agonists hold promise in the treatment of fibromyalgia although current evidence is incomplete." | ( Ablin, JN; Buskila, D, 2013) |
| "However, its possible use in the treatment of fibromyalgia (FM) was never demonstrated." | ( Albuquerque-Júnior, RL; Araújo, AA; Bonjardim, LR; Camargo, EA; DeSantana, JM; Lucca-Júnior, W; Menezes, PP; Nascimento, SS; Quintans-Júnior, LJ, 2014) |
| "The pharmacological treatment of fibromyalgia is limited to a few drugs that have been demonstrated to be moderately effective in some but not all dimensions of the disease." | ( Calandre, EP; Rico-Villademoros, F; Slim, M, 2014) |
| "To develop novel therapies for the treatment of fibromyalgia, we explored pain therapeutic actions of existing pharmaceuticals, which inhibit the somatic symptoms frequently observed in fibromyalgia patients." | ( Mukae, T; Uchida, H; Ueda, H, 2015) |
| "Minalcipran has been approved for the treatment of fibromyalgia in several countries including Australia." | ( Abtroun, L; Bunouf, P; Gendreau, RM; Vitton, O, 2016) |
| "It is not licensed for the treatment of fibromyalgia, but is commonly used because fibromyalgia can respond to the same medicines as neuropathic pain." | ( Cooper, TE; Derry, S; Moore, RA; Wiffen, PJ, 2017) |
| "Two studies tested gabapentin to treat fibromyalgia pain." | ( Cooper, TE; Derry, S; Moore, RA; Wiffen, PJ, 2017) |
| "Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin." | ( Costa, J; Ferreira-Dos-Santos, G; Sousa, DC; Vaz-Carneiro, A, 2018) |
| "MC is an effective treatment for fibromyalgia, with nearly zero % withdrawal from this treatment." | ( Habib, G; Levinger, U, 2020) |
| "In this analysis of a pharmacological treatment for fibromyalgia, most pain summary measures indicated similar effects; improvements in Maximum Pain and Pain Variability contributed to understanding PGIC over Average Pain." | ( Broderick, JE; Junghaenel, DU; Ono, M; Schneider, S; Stone, AA, 2021) |
| "The efficacy of treatments for fibromyalgia is limited and many factors have been identified to trigger the current complaints." | ( Aydemir, AE; Gürcü, S; Hamarat, H; Kıvanç, BK, 2023) |